Abstract:Lamin A/C gene ( LMNA ) mutations contribute to severe striated muscle laminopathies, affecting cardiac and skeletal muscles, with limited treatment options. In this study, we delve into the investigations of five distinct LMNA mutations, including three novel variants and two pathogenic variants identified in patients with muscular laminopathy. Our approach employs zebrafish models to comprehensively study these variants. Transgenic zebrafish expressing wild-type LMNA and each mutation undergo extensive morphological profiling, swimming behavior assessments, muscle endurance evaluations, heartbeat measurement, and histopathological analysis of skeletal muscles. Additionally, these models serve as platform for focused drug screening. We explore the transcriptomic landscape through qPCR and RNAseq to unveil altered gene expression profiles in muscle tissues. Larvae of LMNA (L35P), LMNA (E358K), and LMNA (R453W) transgenic fish exhibit reduced swim speed compared to LMNA (WT) measured by DanioVision. All LMNA transgenic adult fish exhibit reduced swim speed compared to LMNA (WT) in T-maze. Moreover, all LMNA transgenic adult fish, except LMNA (E358K), display weaker muscle endurance than LMNA (WT) measured by swimming tunnel. Histochemical staining reveals decreased fiber size in all LMNA mutations transgenic fish, excluding LMNA (WT) fish. Interestingly, LMNA (A539V) and LMNA (E358K) exhibited elevated heartbeats. We recognize potential limitations with transgene overexpression and conducted association calculations to explore its effects on zebrafish phenotypes. Our results suggest lamin A/C overexpression may not directly impact mutant phenotypes, such as impaired swim speed, increased heart rates, or decreased muscle fiber diameter. Utilizing LMNA zebrafish models for drug screening, we identify l -carnitine treatment rescuing muscle endurance in LMNA (L35P) and creatine treatment reversing muscle endurance in LMNA (R453W) zebrafish models. Creatine activates AMPK and mTOR pathways, improving muscle endurance and swim speed in LMNA (R453W) fish. Transcriptomic profiling reveals upstream regulators and affected genes contributing to motor dysfunction, cardiac anomalies, and ion flux dysregulation in LMNA mutant transgenic fish. These findings faithfully mimic clinical manifestations of muscular laminopathies, including dysmorphism, early mortality, decreased fiber size, and muscle dysfunction in zebrafish. Furthermore, our drug screening results suggest l -carnitine and creatine treatments as potential rescuers of muscle endurance in LMNA (L35P) and LMNA (R453W) zebrafish models. Our study offers valuable insights into the future development of potential treatments for LMNA -related muscular laminopathy.

Normal and aberrant splicing of LMNA

Exploring the Crosstalk Between LMNA and Splicing Machinery Gene Mutations in Dilated Cardiomyopathy

Advances in research on the relationship between the LMNA gene and human diseases (Review)

A new laminopathy caused by an Arg133/Leu mutation in lamin A/C and the effects thereof on adipocyte differentiation and the transcriptome.

[Laminopathies--one Gene, Multiple Diseases].

In Silico and In Vivo Analysis of Amino Acid Substitutions That Cause Laminopathies

A lamin A/C variant causing striated muscle disease provides insights into filament organization

LMNA p.Arg624His missense variant reduces lamin expression at mRNA level: elucidating molecular pathways toward cardiac involvement in laminopathies

Low‐density Lipoprotein Receptor‐related Protein 6 Regulates Alternative Pre‐mrna Splicing

Aberrant and alternative splicing in skeletal system disease.

[Research Progress in A-type Lamins].

Characterization of cardiac involvement in patients with LMNA splice-site mutation–related dilated cardiomyopathy and sudden cardiac death

LMNA -Related Dilated Cardiomyopathy: Single-Cell Transcriptomics during Patient-derived iPSC Differentiation Support Cell type and Lineage-specific Dysregulation of Gene Expression and Development for Cardiomyocytes and Epicardium-Derived Cells with Lamin A/C Haploinsufficiency

From gene to mechanics: a comprehensive insight into the mechanobiology of LMNA mutations in cardiomyopathy

An alpha-helix variant p.Arg156Pro in LMNA as a cause of hereditary dilated cardiomyopathy: genetics and bioinfomatics exploration

Global Proteomic Analysis Reveals Alterations in Differentially Expressed Proteins between Cardiopathic Lamin A/C Mutations

Creatine and l-carnitine attenuate muscular laminopathy in the LMNA mutation transgenic zebrafish

LMNA-related Muscular Dystrophy Involving Myoblast Proliferation and Apoptosis Through the FOXO1/GADD45A Pathway.

Clinical and Functional Characterization of a Novel Mutation in Lamin A/C Gene in a Multigenerational Family with Arrhythmogenic Cardiac Laminopathy

Nuclear Abnormalities in LMNA p.(Glu2Lys) Variant Segregating with LMNA-Associated Cardiocutaneous Progeria Syndrome

The clinical outcome of LMNA missense mutations can be associated with the amount of mutated protein in the nuclear envelope